Neuron23 is a developer of drugs intended to treat Parkinson’s disease and Alzheimer’s disease. Founded in 2018, Neuron23 is backed by investors that include Perceptive Advisors, Kleiner Perkins, Redmile Group, Westlake Village BioPartners, and Surveyor Capital and is headquartered in San Francisco.